title: Effect of dialysate sodium reduction on body water volume, blood pressure, and inflammatory markers in hemodialysis patients--a prospective randomized controlled study.
abstract: Accumulating evidence suggests an association between body volume overload and inflammation in chronic kidney diseases. The purpose of this study was to evaluate the effect of dialysate sodium concentration reduction on extracellular water volume, blood pressure (BP), and inflammatory state in hemodialysis (HD) patients. In this prospective controlled study, adult patients on HD for at least 90 days and those with C-reactive protein (CRP) levels ≥ 0.7 mg/dL were randomly allocated into two groups: group A, which included 29 patients treated with reduction of dialysate sodium concentration from 138 to 135 mEq/L; and group B, which included 23 HD patients not receiving dialysate sodium reduction (controls). Of these, 20 patients in group A and 18 in group B completed the protocol study. Inflammatory, biochemical, hematological, and nutritional markers were assessed at baseline and after 8 and 16 weeks. Baseline characteristics were not significantly different between the two groups. Group A showed a significant reduction in serum concentrations of tumor necrosis factor-α, and interleukin-6 over the study period, while the BP and extracellular water (ECW) did not change. In Group B, there were no changes in serum concentrations of inflammatory markers, BP, and ECW. Dialysate sodium reduction is associated with attenuation of the inflammatory state, without changes in the BP and ECW, suggesting inhibition of a salt-induced inflammatory response.
authors: Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, Botucatu, SP, Brazil.
authors: Gabriela Carvalho
authors: GC
authors: Beduschi
authors: Lidiane Silva Rodrigues
authors: LS
authors: Telini
authors: Jacqueline Costa Teixeira
authors: JC
authors: Caramori
authors: Luis Cuadrado
authors: LC
authors: Martin
authors: Pasqual
authors: P
authors: Barretti
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D015314:Dialysis Solutions / Q000494:pharmacology* / Q000627:therapeutic use; D045604:Extracellular Fluid / Q000187:drug effects*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis; D012964:Sodium / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D015314:Dialysis Solutions; D012964:Sodium